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Summary This paper deals with the utility of immunoliposomes for the delivery of doxorubicin (DXR) to
human ovarian carcinoma cells in vitro and in vivo. We aimed to investigate whether immunoliposome-
mediated targeting of DXR to ovarian cancer cells translates in an enhanced anti-tumour effect compared with
that of non-targeted DXR liposomes (lacking the specific antibody). Target cell binding and anti-tumour
activity of DXR immunoliposomes were studied in vitro and in vivo (xenograft model of ovarian carcinoma). In
vitro we observed that target cell binding and cell growth inhibition of DXR immunoliposomes is superior to
that of non-targeted DXR-liposomes. However, in vivo, despite the efficient target cell binding and good anti-
tumour response of DXR-immunoliposomes, no difference in anti-tumour effect, compared with non-targeted
DXR-liposomes, could be determined. The results indicate that premature DXR leakage from immunolipo-
somes occurring before the actual target cell binding and subsequent DXR association with the tumour cells,
explains why no significant differences in anti-tumour activity between DXR-immunoliposomes and non-
targeted DXR-liposomes were observed in vivo.
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Ovarian cancer is associated with a high incidence and the
highest mortality compared with other gynaecological
malignancies. As ovarian carcinoma remains confined to the
peritoneal cavity throughout most of its clinical course, this
type of cancer is an attractive candidate for intraperitoneal
(i.p.) chemotherapy (Straubinger et al., 1988; Markman,
1991; Nassander et al., 1992). Clinical pharmacokinetic
studies have demonstrated that i.p. administration results in
higher concentrations of drug at the site of disease, whereas
systemic plasma concentrations, and therefore systemic
toxicity, remain lower than after intravenous (i.v.) adminis-
tration. Local anti-tumour activity after i.p. chemotherapy
may therefore be expected to be higher with lower systemic
toxicity.
Intraperitoneal administration of doxorubicin (DXR), a
powerful broad-spectrum antineoplastic agent, is greatly
hampered by local toxicity, in particular dose-limiting
peritonitis. Therefore, investigators did not continue to use
DXR for i.p. chemotherapy of ovarian carcinoma (Ozols et
al., 1982; Deppe et al., 1985; Markman et al., 1989).
Preclinical and clinical evidence shows that the local
inflammatory reaction produced by DXR is reduced by
encapsulation of DXR in liposomes (Forssen and Tokes,
1981; Delgado et al., 1989). In a phase I/II trial it was shown
that DXR-liposomes can be administered i.p. with minimal
peritonitis up to a three times higher dose per cycle than free
DXR (Delgado et al., 1989). Even then, maximum tolerable
dose was not reached with DXR-liposomes.
Earlier, we and others have shown that the use of
antibodies to direct drugs encapsulated in liposomes to
tumours creates an interesting possibility for increasing the
specificity and efficacy of i.p. chemotherapy of tumours
located in the peritoneal cavity (Straubinger et al., 1988;
Singh et al., 1991; Nassander et al., 1992). To target the
liposomes specifically to the tumour cells present in the
peritoneal cavity, Fab' fragments of the monoclonal antibody
OV-TL3, which is directed against the antigen OA3 present
on over 90% of all human ovarian carcinomas, were coupled
to the surface of the liposomes. When administered i.p., such
OV-TL3-immunoliposomes bind rapidly and efficiently (more
than 80% of the injected i.p. dose) to human ovarian cancer
cells located in the peritoneal cavity of nude mice (Nassander
et al., 1992).
The aim of this study was to investigate whether
immunoliposome-mediated targeting of DXR to ovarian
cancer cells translates into an enhanced anti-tumour effect
compared with non-targeted DXR-liposomes (lacking the
antibody). Target cell binding and anti-tumour activity of
DXR-immunoliposomes were studied in vitro and in vivo. The
i.p. growing NIH:OVCAR-3 tumour was chosen for in vivo
evaluation as this model has many features in common with
clinical disease, including development of abdominal disease,
ascites formation and expression of the tumour-associated
antigen OA3 (Hamilton et al., 1984; Poels et al., 1986;
Moseley et al., 1988; Boerman et al., 1990). This is the first
report describing the in vivo anti-tumour activity of DXR-
immunoliposomes in a xenograft model of i.p. growing
ovarian carcinoma.
Materials and methods
Materials
Fetal calf serum (FCS) was obtained from Bocknek
Laboratories, Canada. RPMI-1640 medium supplemented
with 25 mM Hepes buffer and L-glutamine were obtained
from Gibco (Breda, The Netherlands). Dulbecco's modified
Eagle's medium (DMEM) was supplied by ICN Flow
(Zoetermeer, The Netherlands). F(ab')2 fragments of the
monoclonal antibody OV-TL3 were donated by Centocor
EuropeBV (Leiden, The Netherlands). DXR was a gift from
Pharmachemie (Haarlem, The Netherlands). Egg phosphati-
dylcholine (EPC), cholesterol (CHOL), trichloroacetic acid
(TCA), dithiothreitol (DTT) and sulphorhodamine-B (SRB)
were obtained from Sigma (St Louis, MO, USA). Egg-
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phosphatidylglycerol (EPG) was a gift from Nattermann
Phospholipid GmbH (Cologne, Germany). Phosphatidyletha-
nolamine (PE) was obtained from Nutfield Nurseries Lipid
Products (Nutfield, UK). Succinimidyl 4-(p-maleimidophe-
nyl)butyrate was obtained from Pierce (Rockford, USA).
[la,2a(n)-3H]Cholesteryl oleyl ether, [U-_4C]sucrose and
[14-`4C]doxorubicin hydrochloride were obtained from
Amersham (Buckinghamshire, UK). All other reagents were
of analytical grade.
Monoclonal antibody
The murine monoclonal antibody OV-TL3 is directed against
the OA3 antigen, present on over 90% of all human ovarian
carcinomas (Poels et al., 1986; Boerman et al., 1990; Massuger
et al., 1991). F(ab')2 fragments ofOV-TL3 were incubated with
20 mm DTT in acetate buffer at pH 5.5 (100 mM sodium
acetate, 63 mM sodium chloride, 1 mM EDTA) for at least
90 min at room temperature (Nassander et al., 1995). DTT was
removed by applying the incubation mixture onto a Sephadex
G-25M column (PD-10; Pharmacia, Woerden, The Nether-
lands). Elution occurred with acetate buffer pH 6.5 (100 mM
sodium acetate, 40 mM sodium chloride, 1 mM EDTA,
deoxygenated and flushed with nitrogen before use). Fab'
fragments appearing in the void volume were used immediately
for covalent attachment to freshly prepared liposomes contain-
ing the anchor molecule N-[4-(p-maleimidophenyl)butyryl]
phosphatidylethanolamine (MPB-PE).
Preparation of immunoliposomes
MPB-PE was synthesised, purified and analysed as described
above (Martin and Papahadjopoulos, 1982; Nassander et al.,
1995). MPB-PE was incorporated into the liposomal bilayers
to allow covalent coupling of Fab' fragments to the liposomal
surface. The composition of the bilayer of the liposomes used
was EPC:EPG:CHOL:MPB-PE at a molar ratio of
38.1:4:32:1.9. For cell binding and biodistribution experi-
ments, traces of [3H]cholesteryl oleyl ether were added. A
mixture of the appropriate amounts of lipids in chloroform
was evaporated to dryness in a rotary evaporator at 35°C
under reduced pressure. After flushing the lipid film with
nitrogen for at least 20 min, the lipid film was hydrated in a
120 mM ammonium sulphate solution containing 1 mM
desferal. After ten freeze-thaw cycles (freezing in liquid
nitrogen at - 196°C, thawing at 60°C), the resulting liposome
dispersion was sequentially extruded through polycarbonate
membrane filters with 0.6 ,um and 0.2 gim pore size (Unipore,
Biorad, Richmond, CA, USA) under nitrogen pressures up to
0.8 MPa, which resulted in a mean particle size of
approximately 0.25 ,um.
The liposomes were loaded with DXR by creating an
ammonium sulphate gradient as described recently (Haran et
al., 1993). After extrusion, the external medium of the
liposomes was replaced by a glucose (0.2 M)-sodium chloride
(37.5 mM) solution using ultracentrifugation (100 000xg,
45 min). Then, liposomes were incubated with DXR for
30 min at 40°C (incubation conditions 15 Himol total lipid
(TL) per ml; 1 mg DXR ml-1; 1 mM desferal). Non-
encapsulated DXR was removed using the cation exchange
resin Dowex 50WX-4 (Storm et al., 1985). The liposomes
were centrifuged (100 000 xg, 30 min) and the pellet was
redispersed in acetate buffer pH 6.5. The freshly prepared
DXR-liposomes containing the anchor molecule MPB-PE
were mixed with freshly prepared Fab' fragments (concen-
trations during incubation ranged from 6-12 Mmol TL per
ml and 0.25-0.35 mg Fab' per ml respectively). The coupling
reaction was carried out overnight at 4°C under constant
rotation in nitrogen atmosphere.
Finally, the DXR-immunoliposomes were separated from
unconjugated Fab' fragments by ultracentrifugal sedimenta-
tion at 100 000 xg for 30 min. The pellet was resuspended
and washed twice with Hepes buffer (20 mM Hepes, 149 mM
sodium chloride, 1 mM EDTA, pH 7.4). MPB-PE-containing
liposomes that were not incubated with Fab' fragments are
referred to as non-targeted liposomes throughout this paper.
Liposome dispersions were stored at 2-80C and used within
3 weeks after preparation.
Liposome characterisation
Lipid phosphate was determined by the colorimetric method of
Fiske and Subbarow (1925). The amount ofprotein coupled to
the liposomes was determined by the method of Wessel and
Fluigge (1984), with bovine serum albumin as standard. The
amount ofmonoclonal antibody coupled to the liposomes was
expressed as /g Fab' per jmol TL. DXR was determined
fluorimetrically after destruction ofthe liposomes with acidified
ethanol (94% ethanol, 0.3 M hydrochloride acid; excitation
wavelength 490 nm, emission wavelengths 591nm). Radio-
activity of the liposomal dispersions was assayed with Hionic-
Fluor (Packard Instruments, Downers Grove, Illinois, USA) as
scintillation mixture and counted in a Tri-Carb 1500 liquid
scintillation counter (Packard Instruments). Mean particle size
was determined by dynamic light scattering with a Malvern
4700 system using a 25 mW helium-neon laser and the
Automeasure version 3.2 software (Malvern, Malvern, UK).
Forviscosity and refractive index the values ofpure water were
used. As a measure of the particle size distribution of the
dispersion, the system reports apolydispersity index. This index
ranges from 0.0 for an entirely monodisperse up to 1.0 for a
polydisperse dispersion.
Tumour cell line
The human ovarian cancer cell line NIH:OVCAR-3
originated from Dr TC Hamilton (Hamilton et al., 1983,
National Cancer Institute, Bethesda, MD, USA). The
NIH:OVCAR-3 cells were maintained in DMEM supple-
mented with heat-inactivated FCS (10%), glutamine (2 mM),
penicillin (100 units ml-'), streptomycin (100 jug ml-') and
amphotericin B (0.26 ,ug ml-1).
In vitro cell growth inhibition
In vitro cell growth inhibition was determined by the SRB
assay which involves the measurement of cellular protein,
using the dye sulforhodamine-B (SRB) (Rubinstein et al.,
1990; Skehan et al., 1990). Briefly, ovarian tumour cells
cultured as monolayers were treated with trypsin/EDTA
(0.05%/0.02%) and washed with medium. Subsequently, cells
(4 x I0 ml-1) were incubated in suspension for 30 min at
37°C with DXR-immunoliposomes, non-targeted DXR-
liposomes or free DXR. After the incubation, unbound
liposomes and remaining free DXR were removed by
centrifugation (500 xg, 3 min). The cell pellet was washed
twice and resuspended in culture medium. Then, 4 x 104 cells
per well were seeded in a flat bottom 96-well plate and
cultured for 72 h at 37°C and 5% carbon dioxide. The
cultures were fixed with 5% trichloroacetic acid (TCA) at 4°C
for 1-2 h, washed with water and finally stained with 0.4%
SRB dissolved in 1% acetic acid. After 20 min, the plates
were washed with 1% acetic acid and air dried. The bound
dye was dissolved in 10 mM Tris and the optical density was
measured at 490 nm using a Biorad novapath microplate
reader (Biorad Laboratories, Veenendaal, The Netherlands).
The cytotoxic activity of DXR is expressed as relative cell
growth, which is defined as the degree of cell proliferation
relative to that of non-treated cells (= 100%) and is presented
as IC50, i.e.the DXR concentration that induces 50% cell
growth inhibition compared with non-treated cells.
Binding of DXR-immunoliposomes to ovarian cancer cells in
vitro
In vitro cell binding of DXR-(immuno)liposomes was studied
using DXR-liposomes containing 3H-labelled cholesteryl oleyl
ether. OVCAR-3 cells were harvested as described above andincubated with the radiolabelled liposomes at 37°C for 30 or
90 min under the following conditions: 4 x 105 cells ml-', 0-
0.88 jimol TL ml-' and 0-14 jig DXR ml-'. Unbound
liposomes were separated from the cells by centrifugation
(500 x g, 5 min). The cell pellet was washed twice with
medium, mixed with 1 ml Soluene-350 (Packard) and
digested at 40°C overnight. Radioactivity was measured as
described above.
The amount of DXR associated with OVCAR-3 cells was
studied by fluorescence analysis. OVCAR-3 cells (1 x 105
cells ml-') were incubated in suspension at 37°C for 30 min
with DXR-immunoliposomes or non-targeted DXR-lipo-
somes at a DXR concentration of 125 jig ml-'. Unbound
liposomes were separated from the cells by centrifugation
(500 x g, 5 min). The cell pellet was washed twice with ice-
cold medium, resuspended in 0.5 ml 0.25% paraformalde-
hyde in PBS and kept on ice until fluorescence was measured.
Fluorescence analysis was performed using a single laser
FACScan, at a wavelength >650 nm (Becton and Dickinson
Immunocytometry Systems, Mountain View, CA, USA).
Animals and tumour model
NMRI athymic nude mice (Rygaard and Friis, 1974) were
bred at Harlan CPB (HsdCpn:NMRI-nu, Zeist, The
Netherlands). The animals were housed throughout the
experiment under specified pathogen-free conditions in
sterile filter-top cages. They received sterile standard food
(SRM-A, Hope Farms, Woerden, The Netherlands) and
acidified sterile water ad libitum. At the start of the
experiment the animals were 5-10 weeks old.
The tumour cell line NIH:OVCAR-3 was propagated
intraperitoneally as described earlier (Nassander et al., 1992).
At 3-week intervals ascites was harvested from the donor
animals by rinsing the peritoneal cavity with plain RPMI-
1640 medium. Cells were centrifuged once (500 x g, 5 min)
and resuspended in plain RPMI-1640 medium at a
concentration of approximately 4 x I07 vital cells ml-l
(vitality determined by trypan blue dye exclusion); 0.5 ml of
this cell suspension was injected i.p. per mouse. The nude
mice developed a reproducibly growing ascitic tumour with
only minor solid tumour growth.
In vivo anti-tumour activity
Animals were treated 7 days after tumour cell inoculation
with a single i.p. injection of DXR-(immuno-)liposomes at
a dose of 0 - 18 mg DXR kg- and 0 -330 jmol TL kg- in
a volume of 0.5 ml. Three weeks after tumour cell
inoculation, the animals were sacrificed and the peritoneal
cavity was rinsed with PBS to collect all free-floating cells.
Cells were centrifuged (500 x g, 5 min) and the pellet weight
was determined. The weight of the collected tumour cells
was used as a parameter for the anti-tumour response.
In vivo distribution studies
Double-radiolabelled immunoliposomes were used to study
the biodistribution of the immunoliposomes after i.p.
administration. [3H]cholesteryl oleyl ether was used as a
marker of the lipid phase. The aqueous phase was labelled
with ['4C]sucrose to study the integrity of the liposomes
with respect to release of the encapsulated aqueous contents
in the peritoneal cavity. It was shown before that i.p.
injected [14C]sucrose is cleared from the peritoneal cavity
within 2 h (Nassander et al., 1992). The uptake in blood,
liver and spleen after 5 h was shown to be very low
(0.03+0.01; 0.15+0.04; 0.01+0.00% of the injected dose
respectively).
Liposomes were administered i.p. to mice bearing the
OVCAR-3 tumour on days 7, 14 and 21 after tumour cell
inoculation. Five hours after injection the radioactivity in
peritoneal washings, blood, liver and spleen was determined
as described before (Niissander et al., 1992). Briefly, under
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light ether anaesthesia blood samples were drawn from the
retroorbital plexus into heparinised tubes. Then, the mice
were sacrificed and the peritoneal cavity was rinsed with
4 x 5 ml PBS. Samples for determination of the total
amount of radioactivity present in the peritoneal cavity
were drawn immediately. Subsequently, the peritoneal cell
suspension was centrifuged (500 xg, 5 min) to spin down
the cells. The supernatant was collected and samples were
drawn to determine the amount of radioactivity present in
the peritoneal cavity, not associated with tumour cells.
Liver and spleen were collected and weighed. Radioactivity
in blood was determined after the addition of Plasmasol
(Packard) and decolorisation with 30% hydrogen peroxide
at 40°C overnight. Radioactivity was assayed with
Plasmasol as scintillation mixture. Blood volume was
taken as 77.8 ml kg-' body weight (Wish et al., 1950).
Samples of peritoneal washings, supernatant, liver and
spleen were digested by the addition of Soluene-350
(Packard) and incubation at 400C overnight, yielding clear
solutions. Radioactivity was assayed with Hionic-Fluor
(Packard) as scintillation mixture. All samples were
counted as described above (see liposome characterisa-
tion). Radioactivity levels measured were converted to the
percentage of the injected i.p. dose. The percentage of
liposomes bound to the OVCAR-3 cells was calculated by
subtracting the percentage of radioactivity present in the
supernatant from the percentage of the radioactivity present
in the peritoneal washings before centrifugation. The
integrity of the liposomes with respect to release of the
aqueous contents was calculated by comparing the ratio of
the readings for the aqueous marker ['4C]sucrose and the
lipid label [3H]cholesteryl oleyl ether before and after
injection.
To study the biodistributrion of the encapsulated drug,
trace amounts of ['4C]DXR were incorporated in DXR-
immunoliposomes. ['4C]DXR-immunoliposomes and non-
targeted ['4C]-DXR-liposomes (2 umol TL and 175 jug DXR
per mouse, i.e. about 6 mg DXR kg-') were administered i.p.
on day 7 after tumour cell inoculation. To study the fate of
the free drug in the peritoneal cavity, free ['4C]DXR (40 Mg
per mouse, i.e. about 1.5 mg DXR kg-') was administered
i.p. on day 21 after tumour cell inoculation. At different time
points after injection the animals were sacrificed and
radioactivity was determined as described above.
Statistics
The effect of different treatments was compard by a two-tail
Student's t-test assuming equal variances with 95% con-
fidence interval. Differences were considered significant when
P-value of comparison was <0.05.
Results
In vitro cell growth inhibition
OV-TL3-immunoliposomes containing DXR were investi-
gated for their cell growth inhibition effect towards in vitro
cultured ovarian cancer cells. In the first series of
experiments, monolayers of cells were incubated with free
DXR or DXR-(immuno)liposomes. However, only minor cell
growth inhibition was observed owing to insufficient cell
binding of immunoliposomes (data not shown). To improve
the degree of cell binding and to mimic a more
therapeutically relevant situation, the immunoliposomes
were incubated with the tumour cells in suspension. The
cell growth inhibition of DXR-immunoliposomes (IC50
32+2 juM) was in the same range as that of free DXR
(IC50 19 +6 jM). The in vitro cell growth inhibition of non-
targeted DXR-lipsomes (lacking the antibody) was clearly
inferior (IC50 630+100 jM) to that of the DXR-immunolipo-
somes (P=6x 10-5). Empty immunoliposomes did not
influence the cell growth at the relevant lipid concentrations
used.lmmunoliposome-mediated doxorubicin delivery
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In vitro cell binding
To investigate whether the cell growth inhibition of DXR-
immunoliposomes requires binding of the immunoliposomes
to the tumour cells, radiolabelled DXR-immunoliposomes
were prepared. In the lipid bilayer of the liposomes
[3H]cholesteryl oleyl ether was incorporated. This label does
not exchange with proteins and is not hydrolysed in cells and
is therefore a useful marker to study cellular association of
liposomes (Stein et al., 1980; Pool et al., 1982). Figure 1 shows
that immunoliposomes bound to the tumour cells to a higher
extent (9.5-13-fold) than non-targeted liposomes, which
showed hardly any binding. The degree of cell binding of
the tumour-specific DXR-immunoliposomes increased in time
and appeared to be dependent on the liposomal lipid
concentration used. It was estimated that at the highest lipid
concentration used about 7000 immunoliposomes were
binding to one tumour cell after 90 min of incubation. A
separate flow cytometry (FACS) experiment confirmed the
need to have a tumour-specific antibody on the external
liposome surface for obtaining cell binding. The mean
fluorescence per cell was 15-fold higher after incubation of
OVCAR-3 cells with DXR-immunoliposomes compared with
non-targeted DXR-liposomes [mean fluorescence 1100 and 70
respectively; blank value (and empty immunoliposomes) about
20]. DXR levels might be underestimated owing to the fact
that DXR-fluorescence is quenched when bound to DNA.
In vivo anti-tumour activity ofDXR-immunoliposomes
Stimulated by the superior cell growth inhibition observed in
vitro, the anti-tumour activity of the tumour-specific DXR-
immunoliposomes was tested in athymic mice bearing i.p. an
ascitic OVCAR-3 tumour. Nude mice developed intraper-
itoneal disease after an i.p. injection of 2 x 107 OVCAR-3
cells. The OVCAR-3 cell line grew as single cells or as cell
clusters in ascites. Solid tumour nodules remaining in the
peritoneal cavity after collecting the ascitic cells were
primarily detected in the lesser sac. As shown in Figure 2,
the total weight of the solid tumour mass was small
compared with the weight of the ascitic tumour cells (over
4 g on day 21) and increased from 0.1 to about 0.4 per mouse
over a 2-week period. The tumour did not invade the organs
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or the wall of the peritoneal cavity. No metastatic tumour
growth could be detected within the liver, spleen, kidneys,
intestines and lymph nodes (superior mesenteric, iliac) or in
tissues outside the peritoneal cavity, e.g. lungs and the
parathymic and mediastinal lymph nodes.
On day 7 after tumour cell inoculation i.p. treatment was
started with DXR-liposomes with and without coupled
tumour-specific OV-TL3 Fab' fragments. The anti-tumour
effect was determined on day 21 after tumour cell inoculation.
Untreated mice showed progressive tumour growth (Figure 3).
The dose-response study reveals a dose-dependent inhibition
oftumourgrowth. However, nodifference in anti-tumour effect
between treatment with DXR-immunoliposomes and non-
targeted DXR-liposomes was observed. At the lowest dose
(0.67mgDXRkg-1) examined, both types of DXR-liposomes
already induced substantial tumour growth inhibition
(P<2 x 10- vs control). A nearly complete inhibition of
tumour growth was obtained at dose levels >2 mg kg-'.
Microscopic differentiation showed that when the determined
tumour load was less than 0.5 g, other cells (e.g. lymphocytes)
rather than viable tumour cells were responsible for the
determined weight.
In vivo distribution of immunoliposomes
To investigate why tumour-specific DXR-immunoliposomes
are not more efficacious in vivo than non-targeted DXR-
liposomes, the degree of binding of immunoliposomes to the
peritoneal tumour cells was determined. These experiments
were performed with double-radiolabelled liposomes.
[3H]Cholesteryl oleyl ether was used as a marker of the
liposomal lipid phase. In addition, ['4C]sucrose was
incorporated in the internal aqueous phase to study the
integrity of the liposomes. Double-radiolabelled immunolipo-
somes and non-targeted liposomes were administered i.p. to
OVCAR-3-bearing nude mice at different times (day 7, 14 or
21) after tumour cell inoculation. On all days ofexamination,
the cell binding of immunoliposomes was much higher
compared with non-targeted liposomes (see Table I). About
5% of the injected 3H-liposomal dose was found in spleen,
liver and blood, 5 h after injection. The integrity of the
liposomes with respect to release of the aqueous contents was
also investigated. Release of sucrose from the liposomes will
be detected as an increase in the 3H/'4C ratio of the injected
liposome preparation. It was calculated that the loss of
sucrose label from both immunoliposomes and non-targeted
liposomes present in the peritoneal cavity was minimal
(< 15%) 5 h after injection, indicating that the bilayer
structure of the liposomes remained intact (results not
shown).
5
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Figure 1 In vitro cell binding of DXR-immunoliposomes.
OVCAR-3 cells were incubated with DXR-immunoliposomes
(O and 0) or unconjugated DXR-liposomes (LI and *) for 30
(0, LI) or 90min (0, *) at 37°C. After washing the cells to
remove unbound liposomes, cell-associated radioactivity was
determined as described under Materials and methods. The
degree of cell binding is expressed as the estimated amount of
liposomes (nmol TL) bound per 106 cells. The Fab'/lipid ratio of
the immunoliposomes was 12Mg OV-TL3 per ,mol TL. The
outcome of a representative experiment is shown.
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Figure 2 Growth of OVCAR-3 in NMRI nude mice. Mice were
injected i.p. with 2 x 107 OVCAR-3 cells (day 0). At days 7, 14
and 21 after tumour cell inoculation, mice were sacrificed for
determination of tumour load [ascitic tumour cells (1) and
solid tumour (LI )]. Values represent the mean tumour
load+s.d. of 8-12 animals.
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Table II Doxorubicin levels associated with peritoneal OVCAR-3
cells after i.p. administration of [14C]DXR-immunoliposomes
Injected '4C-DXR dose (%) associated
wih the tumour cells
Time after Unconjugated Immuno-
administration (h) liposomes liposomes
5 52+2 58+7
24 34+8 35+±2
[14C]-DXR-(immuno)liposomes were administered i.p. into athymic
nude mice on day7 after tumour cell inoculation. Radioactivity was
determined 5h and 24h after administration as described under
Materials and methods. The Fab'/lipid ratio ofthe immunoliposomes
was 19jugOV-TL3per imol Tl. The mean tumourload was 1.3 +0.3g.
Data represent the mean+ s.d. offive animals.
100
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Figure 3 Effect of DXR-immunoliposomes on growth of
OVCAR-3 ovarian carcinoma in vivo. OVCAR-3 tumour-bearing
athymic nude mice were treated with a single i.p. injection on day
7 after tumour cell inoculation. DXR-immunoliposomes ( =Z)
or unconjugated DXR-liposomes (E) were administered in a
volume of about 0.5ml. Control mice received PBS. The i.p.
tumour load was determined on days 21 and 22 after tumour cell
inoculation. Values represent the mean tumour load of 3-4
animals; for the untreated group six animals were used. The Fab'/
lipid ratio of immunoliposomes was 20jug OV-TL3 per ,umol TL.
When the tumour load was less than 0.5 g, the determined weight
was mainly caused by cells other than tumour cells (e.g.
lymphocytes).
To investigate the question, whether the fate of the drug,
doxorubicin, parallels the fate of the liposomes, the
(immuno)liposomes were labelled with [14C]DXR and
administered i.p. on day 7 after inoculation of the
OVCAR-3 cells. Radioactivity associated with the tumour
cells was determined 5 h and 24 h after injection. As shown
in Table II, the percentage cell-bound [14C]DXR was not
significantly different after administration of non-targeted
["4C]DXR-liposomes or ['4C]DXR-immunoliposomes. Appar-
ently, non-targeted liposomes are as effective as the
immunoliposomes in the delivery of DXR to the cancer
cells. The extent of DXR associated with the tumour cells
after administration of non-targeted ['4C]DXR-liposomes was
much higher than expected on the basis of the levels of cell-
associated liposomal 3H label (see Tables I and II). This
observation suggested to us that part of the tumour cell-
associated 14C-DXR must be attributed to binding of
["4C]DXR released from the liposomes. To study this
possibility, the binding of free DXR to the peritoneal
tumour cells was also examined. Free ['4C]DXR was
administered i.p. in ascitic OVCAR-3 tumour-bearing mice
on day 21 after tumour cell inoculation. Figure 4 shows that
["4C]DXR is disappearing from the peritoneal cavity at a slow
rate. Even 24 h after injection of ['4C]DXR 29+4% of the
injected dose was recovered from the peritoneal cavity. In line
with the earlier suggestion, most of the injected amount of
DXR appeared to be associated with the OVCAR-3 cells.
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Figure 4 Recovery of free '4C-DXR in the peritoneal cavity of
OVCAR-3-bearing nude mice. 14C-DXR (40pg per mouse, i.e.
approximately 1.5mg DXRkg-1) was administered i.p. on day 21
after tumour cell inoculation in a volume of 0.5ml. Results are
expressed as the % of the injected dose 14C-DXR present in the
peritoneal cavity (0) and associated with tumour cells (0).
Values represent the mean tumour load of 4-5 animals.
Discussion
The study presented in this paper is concerned with the use of
immunoliposomes (antibody-targeted liposomes) as carriers
for doxorubicin (DXR) for i.p. chemotherapy of ovarian
carcinoma. As a prelude to assessing the anti-tumour activity
of DXR-containing OV-TL3 immunoliposomes towards in
vivo growing human ovarian cancer cells (OVCAR-3), we first
started to evaluate the cytotoxic effects and tumour-cell
binding of DXR-immunoliposomes towards in vitro cultured
OVCAR-3 cells. The in vitro cell growth inhibition of DXR
encapsulated in immunoliposomes was far (200-fold) superior
to DXR encapsulated in similar non-targeted liposomes
(lacking the specific antibody fragments), and almost
equalled the efficacy of the free drug. In line with these
results, effective tumour cell binding was obtained with OV-
TL3 DXR-immunoliposomes and not with non-targeted
DXR-liposomes. The cell binding data are in the same
Table I Effect of i.p. tumour load on the degree of tumour cell binding of immunoliposomes
Tumour load (g)
Day after tumour cell inoculation
1.0 +0.1 (day7)
2.7+0.4 (day 14)
4.6 +0.4 (day21)
Injected 3H dose (%) associated with the tumour cells
Unconjugated liposomes Immunoliposomes
17+ 10
6+3
6+1
42+13*
74±6**
88 + 13**
(Immuno)liposomes containing [3H]-cholesteryl oleyl ether were injected i.p. into athymic nude mice, 7, 14 or
21 days after tumour cell inoculation. Radioactivity was determined 5 h after administration as described under
Materials and methods. The Fab'/lipid ratio of the immunoliposomes was 30 ig OV-TL3 per ,mol TL. Data
represent the mean±s.d. of4-6 animals. *P<0.05; **P<0.0001 (immunoliposomes vs unconjugated liposomes
on the same day after tumour cell inoculation).
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range as those reported earlier obtained in cell binding
experiments with OV-TL3 immunoliposomes without DXR
(Nassander et al., 1995), indicating that inclusion of DXR
does not interfere with the cell binding of immunoliposomes.
As the combined in vitro results on target cell binding and
cytotoxicity ofDXR-(immuno)liposomes strongly suggest that
specific binding to the cells is conferring greater tumour
cytotoxicity, studies were initiated to evaluate the i.p. anti-
tumour effects in vivo. The i.p. growing OVCAR-3 tumour was
used because of resemblance to human in situ ovarian
carcinoma in terms ofmorphology, histology and synthesis of
tumour-specific antigens (Hamilton et al., 1984). The
characteristics of ovarian carcinoma, i.e. it usually remains
within the peritoneal cavity and rarely disseminates to distant
body sites, were confirmed. In an earlier study we reported that
OV-TL3 immunoliposomes bind rapidly and efficiently (over
80% of the injected dose on day 21 after tumour cell
inoculation) in this xenograft model. In vivo target cell binding
experiments confirmed these data and showed that the
observed degree of tumour cell binding is dependent on the
day of administration (i.e. the tumour load). As shown in
Figure 3, both DXR-immunoliposomes and non-targeted
DXR-liposomes induced a pronounced anti-tumour effect.
However, no difference in anti-tumour activity between the
targeted and non-targeted formulation was observed. Thus,
despite the observation ofspecific binding ofthe immunolipo-
somes to the tumour cells, differences in anti-tumour response
exerted by the DXR-immunoliposomes and non-targeted
DXR-liposomes were observed only in vitro and not in vivo.
One likely explanation for this discrepancy is the occurrence of
considerable drug leakage from the administered specific and
non-specific DXR-liposomes induced by the peritoneal
environment. Rapid, premature drug loss may have over-
shadowed the occurrence of specific immunoliposome-
mediated anti-tumour effects. Studies with radiolabelled
DXR showed that practically all DXR recovered from the
peritoneal cavity was associated with the tumour cells after i.p.
administration offree DXR (Figure 4). Likewise, DXR leaked
from DXR-immunoliposomes or non-targeted DXR-lipo-
somes present in the peritoneal cavity will rapidly associate
with the tumour cells. The observation that the non-targeted
liposomes, which show little cell binding, are able to deliver as
much DXR to the target cells as the specific immunoliposomes
(Table II) strongly indicates that a large part of the liposomal
DXR content is rapidly lost from the non-targeted liposomes.
Considering the identical lipid composition, it is reasonable to
assume that the extent of DXR leakage was similar for the
targeted liposomes. Therefore, leakage and subsequent rapid
association with the tumourcells islikely to explain the absence
of any differences in anti-tumour response exerted by the
immunospecific and non-specific DXR-liposomes and makes it
difficult to discriminate between DXR anti-tumour activity
induced by cell-bound and non cell-bound liposomes. The fact
that differences in tumour cell growth inhibition were observed
in vitro and not in vivo probably relates to the different
composition of the incubation medium compared with ascites
and the much shorter incubation time (30 min) compared with
the long residence time in the peritoneal cavity of the mice.
Considering that the majority of the injected DXR
molecules associate rapidly with the OVCAR-3 cells after
i.p. injection, it is clear that the anti-tumour activity of free
DXR is not easily improved by (immuno)liposome-mediated
delivery. Other cytostatics with less affinity for the tumour
cells should be considered as more promising candidates for
immunoliposome-mediated delivery in this tumour model.
After cell binding of immunoliposomes, the encapsulated
drug can enter the cell via different routes. Firstly, the
immunoliposomes can be taken up by endocytosis. However,
Nassander et al. (1995) showed that internalisation by these
tumour cells takes place only to a low degree. Secondly, the
liposomal contents can be released slowly after tumour cell
binding, providing high DXR concentrations near the
tumour cell surface. The results presented in this paper
indicate that premature drug leakage occurring before
binding of the immunoliposomes to the tumour cells plays
a more important role in the mechanism of DXR uptake in
this tumour model than leakage from cell-bound immuno-
liposomes. One way to improve the situation for DXR-
immunoliposomes in this model is to prevent premature drug
leakage by manipulation of the lipid bilayer composition. By
the selection of phospholipids with higher phase transition
temperatures, more stable DXR-liposomes can be prepared.
However, the more rigid DXR-immunoliposomes were not
nearly as effective as free DXR and the more fluid-type
immunoliposomes used in this study (results not shown). This
would indicate to us that cell-bound rigid immunoliposomes
do not sufficiently release the encapsulated drug. To improve
the therapeutic availability of the entrapped drug, triggered
destabilisation of cell-bound rigid immunoliposomes seems a
better option. After binding of stable DXR-immunolipo-
somes to the tumour cells and clearance of unbound DXR-
liposomes from the peritoneal cavity, destabilisation by, for
example, raising the temperature (then temperature-sensitive
liposomes should be used, e.g. Yatvin et al., 1978; Maruyama
et al., 1993), or lowering the pH (pH-sensitive liposomes,
reviewed by Torchilin et al., 1993) might lead to efficient
tumour cell kill.
In summary, the in vitro cell growth inhibition of DXR
encapsulated in OV-TL3 immunoliposomes is superior to
that of non-targeted DXR-liposomes (lacking the specific
antibody). In tumour-bearing nude mice, however, no
difference in anti-tumour effect could be determined between
targeted and non-targeted DXR-liposomes. Our results
indicate that premature DXR leakage from (immu-
no)liposomes and subsequent DXR association with the
tumour cells, explains why no significant differences in anti-
tumour activity between DXR-immunoliposomes and non-
targeted DXR-liposomes were observed. Further experiments
will be focused on the in vitro and in vivo evaluation ofstable,
temperature-sensitive liposomes, which rapidly release their
contents upon raising the temperature to about 42°C.
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